CDKN2A and glioma: Median overall survival time in patients with IDH-mut glioma without CDKN2A/B deletion was 92.0 months (95%-CI 76.6–107.4) compared to 40.0 months with CDKN2A/B deletion (95%-CI 30.4–49.6); χ2(1) = 42.8; p < 0.001, Log-Rank.